Who
Stelios Papadopoulos
Director
Company insider
Files Form 4 as: Director, Exelixis; Director, Ovid Therapeutics; Director, Regulus Therapeutics; Director, Biogen; Director and 10% owner, Eucrates Biomedical Acquisition; Director, BG Medicine; Director, Anadys Pharmaceuticals; Director, Genvec.
In numbers
- Trades disclosed
- 286
- Buys
- 19
- Sells
- 16
- Bought
- $8.8M
- Sold
- $25.3M
- Companies
- 9
- Companies where not an officer
- 9
- First trade
- 6 Feb 2006
- Last trade
- 27 May 2026
- Last filed
- 29 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 27 May 2026filed 29 May 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code A | —8,367 at $0.00 | filing |
| 27 May 2026filed 29 May 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code A | —8,367 at $0.00 | filing |
| 7 Apr 2026filed 9 Apr 2026 | OVID Ovid TherapeuticsBiotechnology | SEC FORM 4 Code A | $45K17,578 at $2.56 | filing |
| 7 Apr 2026filed 9 Apr 2026 | OVID Ovid TherapeuticsBiotechnology | SEC FORM 4 Code A | $45K17,578 at $2.56 | filing |
| 26 Feb 2026filed 2 Mar 2026 | OVID Ovid Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —65,000 at $0.00 | filing |
| 26 Feb 2026filed 2 Mar 2026 | OVID Ovid Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —65,000 at $0.00 | filing |
| 12 Nov 2025filed 13 Nov 2025 | EXEL ExelixisBiotechnology | SEC FORM 4 Sold | $4.4M100,000 at $43.55 | filing |
| 25 Jun 2025filed 27 Jun 2025 | Regulus Therapeuticsoption or derivative | SEC FORM 4 Code D | —4,650 | filing |
| 25 Jun 2025filed 27 Jun 2025 | Regulus Therapeuticsoption or derivative | SEC FORM 4 Code D | —2,325 | filing |
| 25 Jun 2025filed 27 Jun 2025 | Regulus Therapeuticsoption or derivative | SEC FORM 4 Code D | —4,000 | filing |
| 25 Jun 2025filed 27 Jun 2025 | Regulus Therapeuticsoption or derivative | SEC FORM 4 Code D | —9,000 | filing |
| 25 Jun 2025filed 27 Jun 2025 | Regulus Therapeuticsoption or derivative | SEC FORM 4 Code D | —30,000 | filing |
| 25 Jun 2025filed 27 Jun 2025 | Regulus Therapeuticsoption or derivative | SEC FORM 4 Code D | —15,000 | filing |
| 25 Jun 2025filed 27 Jun 2025 | Regulus Therapeuticsoption or derivative | SEC FORM 4 Code D | —30,000 | filing |
| 25 Jun 2025filed 27 Jun 2025 | Regulus Therapeuticsoption or derivative | SEC FORM 4 Code D | —60,000 | filing |
| 25 Jun 2025filed 27 Jun 2025 | Regulus Therapeuticsoption or derivative | SEC FORM 4 Code D | —59,514 | filing |
| 25 Jun 2025filed 27 Jun 2025 | Regulus Therapeutics | SEC FORM 4 Code U | —976,253 | filing |
| 25 Jun 2025filed 27 Jun 2025 | Regulus Therapeutics | SEC FORM 4 Code D | —64,635 | filing |
| 29 May 2025filed 30 May 2025 | EXEL ExelixisBiotechnology | SEC FORM 4 Code A | —9,812 at $0.00 | filing |
| 15 May 2025filed 16 May 2025 | EXEL Exelixisoption or derivative · Biotechnology | SEC FORM 4 Code M | —20,634 at $0.00 | filing |
News
Citizens Jmp Forecasts Strong Price Appreciation for Exelixis (NASDAQ:EXEL) StockEXEL · tickerreport.com · 21 Oct 2026Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law FirmEXEL · prnewswire.com · 13 Oct 2026
0 headlines in the last 90 days name Stelios Papadopoulos; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.